Breaking News Instant updates and real-time market news.

PFE

Pfizer

$33.65

0.025 (0.07%)

12:03
02/17/17
02/17
12:03
02/17/17
12:03

Pfizer: Data shows similar efficacy profiles for Inflectra and Remicade

Data announced jointly today by Pfizer and Celltrion Healthcare, at the 12th Congress of the European Crohn's and Colitis Organisation, showed that for patients with moderate-to-severe Crohn's disease, treatment with INFLECTRA has similar efficacy and safety to treatment with REMICADE. The randomized 54 week clinical trial in 214 patients met its primary end point demonstrating that, at six weeks, INFLECTRA was similar to REMICADE in the treatment of CD thereby meeting the criterion for non-inferiority. The trial evaluated the number of patients experiencing a fall of 70 points or greater in the Crohn's Disease Activity Index, a well-established assessment of treatment response in CD. The response rates, 71.4% for INFLECTRA and 75.2% for REMICADE, were not statistically significantly different. INFLECTRA is marketed as INFLECTRA in the United States and under other brand names in some countries. "Today's presentation of randomized control trial data in patients with Crohn's disease further supports the existing clinical profile of CT-P13 in inflammatory bowel disease. In addition to existing data from the registration studies, real-world experience and the NOR-SWITCH trial, this data adds to the body of evidence supporting use of CT-P13 across its approved indications," said Sam Azoulay, M.D., Senior Vice President, Chief Medical Officer, Pfizer Essential Health, Pfizer. Additional disease activity measures used in the trial, clinical remission and CDAI-100 response rates, demonstrated similar and consistent efficacy between the two treatments. Six-week data also showed that INFLECTRA had a similar safety and tolerability profile as REMICADE. The number of patients experiencing at least one adverse event, serious adverse events, and adverse events of special interest were similar between the two treatment arms. No new safety signals were identified. Further results on the longer-term safety and efficacy of INFLECTRA from this ongoing 54-week study in CD are expected later this year. The study is also examining the treatment response and safety profile in patients when switched from REMICADE to INFLECTRA, and from INFLECTRA to REMICADE.

  • 21

    Feb

  • 21

    Feb

  • 02

    Mar

  • 09

    Mar

  • 17

    Mar

  • 23

    Mar

  • 01

    Apr

PFE Pfizer
$33.65

0.025 (0.07%)

01/03/17
BRRR
01/03/17
NO CHANGE
Target $15
BRRR
Outperform
Selling OPKO Friday likely a mistake, says Barrington
Investors who sold shares of OPKO Health on Friday's news likely made a mistake, Barrington analyst Michael Petusky tells investors in a research note. The analyst does not believe Pfizer (PFE) would have agreed to the language in the OPKO press release that cited "one or more outliers" if this were not a potentially game-changing issue. Petusky keeps an Outperform rating on shars of OPKO with a $15 price target.
01/09/17
PIPR
01/09/17
NO CHANGE
PIPR
Piper lists Pfizer, Lilly as top 2017 large-cap Pharma picks
Piper Jaffray analyst Richard Purkiss highlights Pfizer (PFE) and Eli Lilly (LLY) as his top large-cap Pharma picks in 2017,saying he prefers "cheaper growth names with limited event risk." With group earnings growth set to halve in 2017 as pipeline momentum stalls, the analyst sees "little likelihood" of sector outperformance. Purkiss calls Merck (MRK) and Johnson & Johnson (JNJ) his least preferred names in large-cap Pharma.
01/20/17
PIPR
01/20/17
NO CHANGE
Target $53
PIPR
Overweight
Pfizer dividend yield back above 4%, says Piper Jaffray
Pfizer's dividend yield breached the 4% level at yesterday's close for the first time since the U.S. Treasury inversion notice that led to the collapse of the Allergan (AGN) deal in early April 2016, Piper Jaffray analyst Richard Purkiss tells investors in a research note. The analyst thinks value-oriented investors should now take a close look at the company's four-year outlook. Purkiss sees Pfizer posting 9.6% annual earnings growth over the next four years and reiterates an Overweight rating on the shares with a $53 price target.
02/15/17
DBAB
02/15/17
NO CHANGE
DBAB
Deutsche not seeing Pfizer buying Bristol-Myers at this time
Following yesterday's speculation of a potential deal, Deutsche Bank analyst Gregg Gilbert said he would be surprised to see Pfizer (PFE) make a move on Bristol-Myers Squibb (BMY) at this stage. Such an acquisition "would represent a very large and concentrated opportunity/risk on immuno-oncology, an area fraught with near-term uncertainty," Gilbert told investors last night in a research note. He believes that if Pfizer were to use $90B for a deal, it would prefer to acquire a more diverse set of value drivers. The analyst keeps a Hold rating on Bristol and Buy rating on Pfizer. Bristol shares rose 3% yesterday to $53.71 amid speculation of a potential takeover. The conjecture had Roche (RHHBY), Novartis (NVS) and Pfizer potentially looking into a bid for Bristol.

TODAY'S FREE FLY STORIES

IBB

iShares Nasdaq Biotechnology Index

$106.07

2.02 (1.94%)

09:50
12/11/17
12/11
09:50
12/11/17
09:50
Technical Analysis
Technical View: iShares Nasdaq Biotechnology Index breaks out »

The iShares Nasdaq…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKS

AK Steel

$5.46

0.13 (2.44%)

09:50
12/11/17
12/11
09:50
12/11/17
09:50
Options
Interest in AK Steel Mar 7 calls continues »

Interest in AK Steel Mar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCE

Spark Therapeutics

$73.38

2.82 (4.00%)

09:48
12/11/17
12/11
09:48
12/11/17
09:48
Conference/Events
Spark Therapeutics to hold a pharmaceutical update conference call »

Management reviews the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 12

    Jan

NKE

Nike

$61.67

0.365 (0.60%)

09:47
12/11/17
12/11
09:47
12/11/17
09:47
Upgrade
Nike rating change  »

Nike upgraded to Positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Dec

09:45
12/11/17
12/11
09:45
12/11/17
09:45
General news
JOLTS Job Openings to be reported at 10:00 »

October JOLTS Job…

IOTS

Adesto Technologies

$7.00

-0.45 (-6.04%)

09:44
12/11/17
12/11
09:44
12/11/17
09:44
Conference/Events
Adesto Technologies management to meet with Roth Capital »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 14

    Dec

AGIO

Agios Pharmaceuticals

$60.97

0.14 (0.23%)

09:42
12/11/17
12/11
09:42
12/11/17
09:42
Conference/Events
Agios Pharmaceuticals to hold an investor meeting »

Investor Meeting where…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

KMB

Kimberly-Clark

09:41
12/11/17
12/11
09:41
12/11/17
09:41
Technical Analysis
Technical View: Kimberly-Clark falls in early trading, analyst action »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKS

AK Steel

, CELG

Celgene

$106.09

3.36 (3.27%)

09:40
12/11/17
12/11
09:40
12/11/17
09:40
Options
Unusually active option classes on open December 11th »

Unusual total active…

AKS

AK Steel

CELG

Celgene

$106.09

3.36 (3.27%)

GME

GameStop

CTL

CenturyLink

X

U.S. Steel

ORCL

Oracle

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 18

    Jan

  • 25

    Mar

09:40
12/11/17
12/11
09:40
12/11/17
09:40
General news
Fed funds futures are flat to lower ahead of Wednesday's FOMC »

Fed funds futures are…

ECR

Eclipse Resources

09:35
12/11/17
12/11
09:35
12/11/17
09:35
Conference/Events
Eclipse Resources to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTE

Baytex Energy

09:35
12/11/17
12/11
09:35
12/11/17
09:35
Downgrade
Baytex Energy rating change  »

Baytex Energy downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNN

Smith & Nephew

09:33
12/11/17
12/11
09:33
12/11/17
09:33
Downgrade
Smith & Nephew rating change  »

Smith & Nephew…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YPF

YPF

09:32
12/11/17
12/11
09:32
12/11/17
09:32
Upgrade
YPF rating change  »

YPF upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMS

Fresenius Medical

09:32
12/11/17
12/11
09:32
12/11/17
09:32
Downgrade
Fresenius Medical rating change  »

Fresenius Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEF

Telefonica

09:31
12/11/17
12/11
09:31
12/11/17
09:31
Downgrade
Telefonica rating change  »

Telefonica downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEX

IDEX Corp.

09:31
12/11/17
12/11
09:31
12/11/17
09:31
Hot Stocks
IDEX Corp. announces acquisition of thinXXS Microtechnology AG »

IDEX Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HD

Home Depot

09:31
12/11/17
12/11
09:31
12/11/17
09:31
Downgrade
Home Depot rating change  »

Home Depot downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

AIBSF

Allied Irish Banks

09:29
12/11/17
12/11
09:29
12/11/17
09:29
Downgrade
Allied Irish Banks rating change  »

Allied Irish Banks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARGX

Argenx

$30.45

0.05 (0.16%)

09:29
12/11/17
12/11
09:29
12/11/17
09:29
Conference/Events
Argenx to hold a workshop »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

VTGN

VistaGen Therapeutics

$1.80

-0.23 (-11.33%)

09:27
12/11/17
12/11
09:27
12/11/17
09:27
Syndicate
VistaGen Therapeutics announces pricing of common stock and warrant offering »

VistaGen announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIT

Fitbit

, CBOE

CBOE Holdings

$125.27

1.08 (0.87%)

09:26
12/11/17
12/11
09:26
12/11/17
09:26
Hot Stocks
On The Fly: Pre-market Movers »

HIGHER: Fitbit (FIT), up…

FIT

Fitbit

CBOE

CBOE Holdings

$125.27

1.08 (0.87%)

NXPI

NXP Semiconductors

$115.29

0.16 (0.14%)

QURE

uniQure

$17.82

0.8 (4.70%)

CSIQ

Canadian Solar

$17.25

0.13 (0.76%)

PZRX

PhaseRx

$1.00

0.0126 (1.28%)

WPC

W.P. Carey

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

NDAQ

Nasdaq

$78.78

0.99 (1.27%)

09:26
12/11/17
12/11
09:26
12/11/17
09:26
Recommendations
Nasdaq analyst commentary  »

Nasdaq price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RPT

Ramco-Gershenson

09:25
12/11/17
12/11
09:25
12/11/17
09:25
Conference/Events
Ramco-Gershenson to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

LITE

Lumentum

$49.60

1.05 (2.16%)

09:23
12/11/17
12/11
09:23
12/11/17
09:23
Upgrade
Lumentum rating change  »

Lumentum upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.